Erenumab Overview

Introduction of Erenumab

Erenumab (AMG-334) is a human IgG2λ monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. With the trade name Aimovig, erenumab has been released and marketed by Novartis and Amgen, and is in fact a novel therapeutic approach as the first and only U.S. Food and Drug Administration (FDA) approved for prevention of migraine in adults.

Mechanism of Action of Erenumab

During a migraine, activated primary sensory neurons (meningeal nociceptors) in the trigeminal ganglion release calcitonin gene-related peptide (CGRP) from their peripherally projecting nerve endings located within the meninges. This CGRP then binds to and activates CGRPR located around meningeal vessels, causing vasodilation, mast cell degranulation, and plasma extravasation. CGRPR is a complex of calcitonin receptor- like receptor (CALCRL) and receptor activity- modifying protein 1 (RAMP1) which includes the CGRP binding pocket. Erenumab targets the extracellular domains of CGRPR, blocking the CGRP-CGRPR signaling, and thereby behaves its efficacy in treatment of migraine.

Fig.1 Mechanism of Action of Erenumab

Clinical Projects of Erenumab*

Approved Drugs of Erenumab**

INN (trade name)	Therapeutic area	Dose	Strength	Route	Company	Marketing start	Market
Aimovig	Migraine	Injection, Solution	10 mg/mL	Intravenous	Amgen Inc.	May 17, 2018

What We Provide

Therapeutic Antibody

Erenumab

We provide high-quality Erenumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Erenumab

** Information presented in the table were collected from the following website:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761077

For research use only. Not intended for any clinical use.